These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 32496677)

  • 1. [Pulmonary arterial hypertension (PAH ) : a new era of pulmonary arterial vasodilatators].
    Guiot J; Cornia O; Louis R
    Rev Med Liege; 2020 May; 75(5-6):344-349. PubMed ID: 32496677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapies in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Guignabert C; Günther S; Girerd B; Jaïs X; Algalarrondo V; Price LC; Savale L; Sitbon O; Simonneau G; Humbert M
    Pharmacol Ther; 2014 Feb; 141(2):172-91. PubMed ID: 24134901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Pulmonary Arterial Hypertension.
    Weatherald J; Varughese RA; Liu J; Humbert M
    Semin Respir Crit Care Med; 2023 Dec; 44(6):746-761. PubMed ID: 37369218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evolution of pathogenetic therapy of pulmonary arterial hypertension].
    Chazova IE; Yarovoy SY; Danilov NM
    Ter Arkh; 2019 Dec; 91(12):4-9. PubMed ID: 32598582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways.
    Mandras S; Kovacs G; Olschewski H; Broderick M; Nelsen A; Shen E; Champion H
    J Cardiovasc Pharmacol Ther; 2021 Sep; 26(5):453-462. PubMed ID: 33836637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
    Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
    Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ＜Editors' Choice＞ Pulmonary Hypertension: Diagnosis, Management, and Treatment.
    Kondo T; Okumura N; Adachi S; Murohara T
    Nagoya J Med Sci; 2019 Feb; 81(1):19-30. PubMed ID: 30962652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel strategies for treatment of pulmonary arterial hypertension.
    Jasińska-Stroschein M; Orszulak-Michalak D
    Postepy Hig Med Dosw (Online); 2017 Jul; 71(0):577-588. PubMed ID: 28791952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis.
    Shivakumar S; Thynne TR; Mohammadi L; Burdeniuk C; Mangoni AA
    Int J Rheum Dis; 2020 Oct; 23(10):1276-1287. PubMed ID: 32691518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of riociguat in combination therapies for pulmonary arterial hypertension.
    Rahaghi FF; Trivieri MG; Sahay S
    Respir Med; 2023 May; 211():107196. PubMed ID: 36889521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in targeted therapy for pulmonary arterial hypertension in children.
    Li L; Zhu X; Chen X; Gao J; Ding C; Zhang M; Ma S
    Eur J Pediatr; 2023 May; 182(5):2067-2076. PubMed ID: 36527480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension.
    Yao A
    J Cardiol; 2012 Nov; 60(5):344-9. PubMed ID: 23068290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of pediatric pulmonary arterial hypertension: A focus on the NO-sGC-cGMP pathway.
    Beghetti M; Gorenflo M; Ivy DD; Moledina S; Bonnet D
    Pediatr Pulmonol; 2019 Oct; 54(10):1516-1526. PubMed ID: 31313530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical therapies for pulmonary arterial hypertension.
    Pulido T; Zayas N; de Mendieta MA; Plascencia K; Escobar J
    Heart Fail Rev; 2016 May; 21(3):273-83. PubMed ID: 26791159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary Arterial Hypertension: Pathophysiology and Treatment.
    Lan NSH; Massam BD; Kulkarni SS; Lang CC
    Diseases; 2018 May; 6(2):. PubMed ID: 29772649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
    Channick R; Preston I; Klinger JR
    Clin Chest Med; 2013 Dec; 34(4):811-24. PubMed ID: 24267306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Pulmonary Arterial Hypertension in the Pediatric Patient.
    Ezekian JE; Hill KD
    Curr Cardiol Rep; 2019 Nov; 21(12):162. PubMed ID: 31781972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Update: Preclinical developments for the treatment of pulmonary arterial hypertension].
    Janssen W; Ghofrani HA; Weissmann N; Grimminger F; Schermuly RT
    Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S157-9. PubMed ID: 19718604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary arterial hypertension: a current review of pharmacological management.
    Sahni S; Ojrzanowski M; Majewski S; Talwar A
    Pneumonol Alergol Pol; 2016; 84(1):47-61. PubMed ID: 26693827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Selection in Pulmonary Arterial Hypertension: Phosphodiesterase Type 5 Inhibitors versus Soluble Guanylate Cyclase Stimulator.
    Watanabe H
    Eur Cardiol; 2018 Aug; 13(1):35-37. PubMed ID: 30310468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.